References
- Korea Central Cancer Registy, National Cancer Center: Annual report of cancer statistics in Korea 2017. Available from http://www.ncc.re.kr. Accessed July 20, 2020.
- National Cancer Information Center: Colorectal cancer. Available from http://www.cancer.go.kr. Accessed July 20, 2020.
- National Comprehensive Cancer Network. Clinical Practice Guideline in OncologyTM, Colon cancer Version 3 (2020). Available from http://www.nccn.org. Accessed July 20, 2020.
- National Comprehensive Cancer Network. Clinical Practice Guideline in OncologyTM, Rectal cancer Version 3 (2020). Available from http://www.nccn.org Accessed July 20, 2020.
- Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. https://doi.org/10.1056/NEJMoa032691
- Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26(12):2013-9. https://doi.org/10.1200/JCO.2007.14.9930
- Van Cutsem E, Kohne CH, Hitreet E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-17. https://doi.org/10.1056/NEJMoa0805019
- Bennouna J, Sastre J, Arnold J, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14(1):29-37. https://doi.org/10.1016/S1470-2045(12)70477-1
- Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15(10):1065-75. https://doi.org/10.1016/s1470-2045(14)70330-4
- Micromedex solutions. IBM Watson Health, Greenwood Village, CO. Available from https://www.micromedexsolutions.com. Accessed July 20, 2020.
- Tanaka H, Takahashi K, Yamaguchi K, et al. Hypertension and proteinuria as predictive factors of effects of bevacizumab on advanced breast cancer in Japan. Biol Pharm Bull 2018;41(4):644-8. https://doi.org/10.1248/bpb.b17-00605
- Jane A, Joseph F, Roaa AG, et al. Drug information handbook 28th ed. North American: Wolters Kluwer, 2019; 281-5.
- Heo H, Choi JS, Im HJ, et al. Hypertension and clinical outcome in metastatic colorectal cancer patients treated with bevacizumab. J. Kor. Soc. Health-Syst. Pharm 2012;29(3):324-37. https://doi.org/10.32429/jkshp.2012.29.3.009
- Yan LZ, Dressler EV, Adams VR. Association of hypertension and treatment outcomes in advanced stage non-small cell lung cancer patients treated with bevacizumab or non-bevacizumab containing regimens. J Oncol Pharm Pract 2018;24(3):209-17. https://doi.org/10.1177/1078155217690921
- Feliu J, Salud A, Safont MJ, et al. Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer. PLoS One 2015;10(1):e0116527. https://doi.org/10.1371/journal.pone.0116527
- Zhao T, Wang X, Xu T, Xu X, Liu Z. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget 2017;8(31):51492-506. https://doi.org/10.18632/oncotarget.18190
- Iwasa S, Nakajima TE, Nagashima K, et al. Lack of association of proteinuria and clinical outcome in patients treated with bevacizumab for metastatic colorectal cancer. Anticancer Res 2013;33(1):309-16.
- Uysal M, Bozcuk H, Göksu SS, et al. Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab. Biomed Pharmacother 2014;68(4):409-12. https://doi.org/10.1016/j.biopha.2014.03.002
- Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 2008;134(5):1296-310. https://doi.org/10.1053/j.gastro.2008.02.098
- Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499-506. https://doi.org/10.1200/JCO.2012.42.8201
- Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010;21(8):1381-9. https://doi.org/10.1681/ASN.2010020167
- Lafayette R, McCall B, Li N, et al. Incidence and relevance of proteinuria in bevacizumab-treated patients: pooled analysis from randomized controlled trials. Am J Nephrol 2014;40(1):75-83. https://doi.org/10.1159/000365156
- Kim H. Differential diagnosis and treatment of proteinuria. Korean J Med 2013;85(4):374-7. https://doi.org/10.3904/kjm.2013.85.4.374